Patent intelligence · US
US 10702629
Conditioning harvested fat for re-injection
Conditioning harvested fat for re-injection
Patent details — US 10702629
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 7, 2020
- Expiration
- Jul 2, 2040
- Applicant
- Black Tie Medical Inc.
- Claims
- 20
- CPC classes
- A61K, A61K35/35
Quick answer
US 10702629 (Conditioning harvested fat for re-injection) is held by Black Tie Medical Inc.. Status: granted. Granted Jul 7, 2020. Expires Jul 2, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Black Tie Medical Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K35/35
More from Black Tie Medical Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 10702629?
US 10702629 (Conditioning harvested fat for re-injection) is held by Black Tie Medical Inc.. Status: granted. Granted Jul 7, 2020. Expires Jul 2, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10702629?
Black Tie Medical Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 10702629 expire?
Our index shows an expiration date of Jul 2, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.